PaxMedica Completes HAT-301 Registrational Trial for PAX-101
01 juin 2023 08h00 HE
|
PaxMedica, Inc.
HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 TARRYTOWN, NY, June 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –...
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
15 mai 2023 16h13 HE
|
PaxMedica, Inc.
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic...
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results
29 mars 2023 19h21 HE
|
PaxMedica, Inc.
-Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023- Fourth Quarter 2022 Highlights Initiated Phase 3 Clinical Program to Advance PAX-101 Towards FDA...
PaxMedica Holds Meeting of Scientific Advisory Board
20 mars 2023 08h00 HE
|
PaxMedica, Inc.
Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S. TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical...
PaxMedica Releases 2022 Shareholder Letter
15 févr. 2023 07h30 HE
|
PaxMedica, Inc.
Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
03 févr. 2023 08h00 HE
|
PaxMedica, Inc.
Additional Capital Will Help Fund Development of PAX-101 TARRYTOWN, NY, Feb. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical...
PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
22 nov. 2022 08h00 HE
|
PaxMedica, Inc.
TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic...
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
17 nov. 2022 20h29 HE
|
PaxMedica, Inc.
-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
15 nov. 2022 08h00 HE
|
PaxMedica, Inc.
-PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15,...
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
08 nov. 2022 08h00 HE
|
PaxMedica, Inc.
Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical...